The global Solubility Enhancement Excipients Market Size is estimated as 57,138 Tons in 2024 and is expected to grow from 62,955 Tons in 2025 to 1,32,081 Tons in 2032 growing at a CAGR of 11.17%.
The Solubility Enhancement Excipients Market plays a vital role in the pharmaceutical industry by addressing the formulation challenges associated with poorly water-soluble drug compounds. As nearly 40% of marketed drugs and over 70% of new chemical entities (NCEs) exhibit low aqueous solubility, excipients that enhance dissolution rates are essential for improving bioavailability and therapeutic efficacy. These excipients include polymers, surfactants, lipids, and complexing agents that aid in solubilizing active pharmaceutical ingredients (APIs) through mechanisms such as solid dispersion, micelle formation, and complexation. The growing demand for oral solid dosage forms, coupled with the shift toward high-potency and low-solubility APIs, is driving the market for advanced excipient technologies. Additionally, increasing R&D investment in novel drug delivery systems and the rise of generic formulations are contributing to the widespread adoption of solubility-enhancing excipients across the pharmaceutical value chain.
The market is segmented by excipient type (polymers, surfactants, lipids, cyclodextrins, others), formulation type (oral, injectable, topical), and end-use (pharmaceutical companies, contract development and manufacturing organizations, academic institutes). Polymers dominate the market due to their versatility and effectiveness in forming solid dispersions and amorphous drug formulations. Surfactants and lipids are increasingly used in lipid-based drug delivery systems and self-emulsifying formulations. Oral formulations hold the largest share owing to patient preference and ease of administration, while the injectable segment is gaining traction for biologics and poorly soluble compounds requiring rapid systemic absorption. North America leads the global market due to strong pharmaceutical manufacturing, regulatory support, and early adoption of novel excipient technologies. Asia-Pacific is emerging as a high-growth region driven by rising generic drug production, contract manufacturing activity, and expansion of local pharmaceutical capabilities. The solubility enhancement excipients market is poised for continued growth, supported by drug innovation trends, advancements in formulation science, and the critical need to improve bioavailability in modern drug development.
|
Global Chemical products and preparations of the chemical or allied industries Trade, Imports, USD million, 2020-24 |
|||||
|
|
2020 |
2021 |
2022 |
2023 |
2024 |
|
World |
62,032 |
67,861 |
70,053 |
77,219 |
80,435 |
|
United States of America Metadata |
13,480 |
15,292 |
16,940 |
19,525 |
20,672 |
|
China Metadata |
3,886 |
5,362 |
5,403 |
5,442 |
5,577 |
|
Netherlands Metadata |
4,036 |
4,769 |
4,709 |
5,301 |
5,450 |
|
Germany Metadata |
4,389 |
4,453 |
4,138 |
4,603 |
4,796 |
|
Mexico Metadata |
1,825 |
1,951 |
2,217 |
2,636 |
3,121 |
|
|
|||||
|
Source: OGAnalysis |
|||||
- United States of America Metadata, China Metadata, Netherlands Metadata, Germany Metadata and Mexico Metadata are the top five countries importing 49.3% of global Chemical products and preparations of the chemical or allied industries in 2024
- United States of America Metadata accounts for 25.7% of global Chemical products and preparations of the chemical or allied industries trade in 2024
- China Metadata accounts for 6.9% of global Chemical products and preparations of the chemical or allied industries trade in 2024
- Netherlands Metadata accounts for 6.8% of global Chemical products and preparations of the chemical or allied industries trade in 2024
|
Global Chemical products and preparations of the chemical or allied industries Export Prices, USD/Ton, 2020-24 |
|
|
|
Source: OGAnalysis |
The solubility enhancement excipients market is growing rapidly due to the high prevalence of poorly water-soluble drug compounds. These excipients are essential in improving drug bioavailability, therapeutic effectiveness, and dosage uniformity in both innovator and generic drug formulations.
Polymers represent the largest excipient category, particularly those used in solid dispersion and amorphous formulations. Hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and polyethylene glycol (PEG) are widely used for their solubilizing and stabilizing properties.
Surfactants are gaining popularity in formulations requiring rapid dissolution or self-emulsifying drug delivery systems. Non-ionic surfactants such as polysorbates and sorbitan esters enhance solubility by reducing surface tension and forming micelles around the drug molecules.
Lipid-based excipients are increasingly used in oral and parenteral dosage forms. They support the formulation of self-microemulsifying and self-nanoemulsifying drug delivery systems (SMEDDS and SNEDDS), which significantly improve solubility and intestinal absorption.
Oral solid dosage forms remain the dominant application area due to their convenience, stability, and patient compliance. However, solubility enhancement in injectables is rising, especially for biologics and targeted therapies requiring fast and complete absorption.
Pharmaceutical companies are the primary users of solubility enhancers, driven by the need to reformulate existing drugs and enhance the viability of new chemical entities. CDMOs are also investing heavily in excipient technologies to offer differentiated formulation services.
North America leads the market owing to strong R&D infrastructure, advanced formulation technologies, and a robust pipeline of poorly soluble drug candidates. Regulatory acceptance of novel excipients also supports market expansion in the region.
Asia-Pacific is experiencing rapid growth due to the rise in generic drug manufacturing, expanding pharmaceutical exports, and increased adoption of advanced excipients in countries like India, China, and South Korea.
Regulatory bodies are encouraging the use of excipients that are both effective and safe, pushing manufacturers to ensure compliance with pharmacopoeial standards and conduct comprehensive compatibility and stability testing.
Innovation in co-processed and multifunctional excipients is transforming formulation strategies. These advanced materials offer combined solubilization, stabilization, and controlled-release functions, streamlining the development process and improving drug performance.
|
Parameter |
Solubility Enhancement Excipients Marketscope Detail |
|
Base Year |
2024 |
|
Estimated Year |
2025 |
|
Forecast Period |
2026-2032 |
|
Market Size-Units |
USD billion |
|
Market Splits Covered |
By Dosage Form, By Excipient Type, By Technology, By End User |
|
Countries Covered |
North America (USA, Canada, Mexico) |
|
Analysis Covered |
Latest Trends, Driving Factors, Challenges, Trade Analysis, Price Analysis, Supply-Chain Analysis, Competitive Landscape, Company Strategies |
|
Customization |
10% free customization (up to 10 analyst hours) to modify segments, geographies, and companies analyzed |
|
Post-Sale Support |
4 analyst hours, available up to 4 weeks |
|
Delivery Format |
The Latest Updated PDF and Excel Data file |
Market Segmentation
Solubility Enhancement Excipients Market, By Technology
Solubility Enhancement Excipients Market, By Excipient Type
Solubility Enhancement Excipients Market, By Dosage Form
Solubility Enhancement Excipients Market, By End User
Solubility Enhancement Excipients Market, By Region
November 2024: Clariant introduced new high-purity excipients including VitiPure LEX 3350 S and 4000 S, along with ultra‑clean polysorbate and castor oil grades for parenteral applications, addressing the need for low endotoxin and microbial levels.
July 2023: Lubrizol launched two novel solubility-enhancing polymers—Apinovex for oral amorphous solid dispersions and Apisolex for injectables—demonstrating improvements in bioavailability and scalable pharmaceutical manufacturing in a dedicated webinar.
December 2022: BASF Pharma Solutions’ Soluplus excipient was accepted into the FDA’s pilot innovation program for novel excipients, marking regulatory acknowledgement of its efficacy in enhancing drug solubility and bioavailability.
March 2022: Evonik introduced EUDRATEC® SoluFlow technology, leveraging microparticle engineering to produce amorphous solid dispersions of poorly soluble small-molecule APIs, facilitating their use in oral drug formulations.
Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM
Need something within your budget? NO WORRIES! WE GOT YOU COVERED!